Drug
Tiragolumab clinical trials
Also written MTIG7192A and RO7092284.
- studies test it
- 58
- open now
- 7
- in phase 3
- 10
- first study started
- 2016
Keep track of what changes. Save the Tiragolumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Combined with it in one product
Studies by the year they started
58 studies that test it; most in 2023 (14)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 2 |
| 2019 | 4 |
| 2020 | 11 |
| 2021 | 9 |
| 2022 | 6 |
| 2023 | 14 |
| 2024 | 2 |
| 2025 | 6 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 19
- Phase 2
- 43
- Phase 3
- 10
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 34 · Other 24
Hoffmann-La Roche (30) · M.D. Anderson Cancer Center (6) · Genentech, Inc. (4) · National Cancer Institute (NCI) (3) · Alliance Foundation Trials, LLC. (2) · Georgetown University (1) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (1) · Mayo Clinic (1)
Often tested with
Tested in the same studies.
Atezolizumab (34) · Bevacizumab (6) · Tocilizumab (4) · Tobemstomig (4) · Cobimetinib (4) · Ipatasertib (4) · Gemcitabine (3) · Inavolisib (3)
Studies
Open first, then newest update. How each study uses Tiragolumab is read from its arms, and is right about nine times in ten.
Testing it · 58
- A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)RecruitingPhase 1Hoffmann-La RocheNCT04929223Written as Tiragolumab
- A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored StudyRecruitingPhase 3Hoffmann-La RocheNCT05862285Written as Tiragolumab
- A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial CancerRecruitingPhase 1/2Alliance Foundation Trials, LLC.NCT04486352Written as Tiragolumab
- Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid TumorsRecruitingPhase 2University Medical Center GroningenNCT05483400Written as Tiragolumab and atezolizumab
- Tiragolumab and Atezolizumab in Advanced Pan-cancer PatientsRecruitingPhase 2OmicoNCT06003621Written as Tiragolumab
- Immunotherapy With CCRT Followed by Surgery for Locally Advanced ESCC PatientsRecruitingPhase 1/2National Taiwan University HospitalNCT05743504Written as Tiragolumab
- Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT)RecruitingPhase 1Centre Georges Francois LeclercNCT05259319Written as Tiragolumab
- Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 TrialActive, not recruitingPhase 2National Cancer Institute (NCI)NCT05715281Written as Tiragolumab
- Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malignancies (TIGER)Active, not recruitingPhase 1M.D. Anderson Cancer CenterNCT06760481Written as Tiragolumab
- A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown PrimaryActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT06754501Written as Tiragolumab
- Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial CarcinomaActive, not recruitingPhase 1/2M.D. Anderson Cancer CenterNCT05394337Written as Tiragolumab
- Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLCActive, not recruitingPhase 2Alliance Foundation Trials, LLC.NCT05798663Written as Tiragolumab
- Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung CancerCompletedPhase 3Hoffmann-La RocheNCT04665856Written as Tiragolumab
- A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular CarcinomaTerminatedPhase 1/2Hoffmann-La RocheNCT05908786Written as Tiragolumab
- A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent ChemoradiotherapyCompletedPhase 3Hoffmann-La RocheNCT04543617Written as Tiragolumab
- Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLCActive, not recruitingPhase 2Georgetown UniversityNCT04958811Written as Tiragolumab
- A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)Active, not recruitingPhase 1/2Hoffmann-La RocheNCT04524871Written as Tiragolumab
- A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal CarcinomaCompletedPhase 3Hoffmann-La RocheNCT04540211Written as Tiragolumab
- A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)TerminatedPhase 1/2Hoffmann-La RocheNCT03281369Written as Tiragolumab
- Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)TerminatedPhase 1/2Hoffmann-La RocheNCT03869190Written as Tiragolumab
See all 58 studies that test Tiragolumab →
Given in every arm · 5 — Tiragolumab is usual care beside what is tested
- NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 TrialRecruitingPhase 2The Netherlands Cancer InstituteNCT06342037Written as Tiragolumab
- A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell CarcinomaActive, not recruitingPhase 2Hoffmann-La RocheNCT05805501Written as Tiragolumab
- Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient TumorsActive, not recruitingPhase 1/2National Cancer Institute (NCI)NCT05286801Written as Tiragolumab
- Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite Stable, Metastatic Colorectal CancerActive, not recruitingPhase 2University of Colorado, DenverNCT06784947Written as Tiragolumab
- A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)CompletedPhase 1/2Hoffmann-La RocheNCT05459129Written as Tiragolumab
Codes
What other systems call Tiragolumab · ClinicalTrials.gg INT002091
- MeSH (NLM) C000730814TiragolumabOne source ClinicalTrials.gov
- UNII (FDA) 6XG22YQM2ZTIRAGOLUMABOne source FDA
- NCI Thesaurus C131291TiragolumabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000730814 | Tiragolumab | One source ClinicalTrials.gov |
| UNII (FDA) | 6XG22YQM2Z | TIRAGOLUMAB | One source FDA |
| NCI Thesaurus | C131291 | Tiragolumab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.